Will Su currently works at FibroGen, a research and development company based in San Francisco, in corporate development and project management on their China program. Will has always had a strong interest in Asia growing up in an immigrant family originally from Taiwan. Now he spends his time focusing on bringing novel therapies to alleviate unmet medical needs in China and greater Asia. Will prepared the New Drug Application for Roxadustat, a first-in-class drug for anemia in Chronic Kidney Disease (CKD), for submission to the Chinese FDA. In addition, he is now working on medical affairs to prepare China for the commercialization of Roxadustat as well as another project to introduce a biosynthetic cornea medical device to help corneal blindness patients see again.
Will brings nonprofit and governance experience to VIA having previously served on and been the Chair of a 501(c)3 corporation. He is excited to advance the mission of VIA. Will holds a Bachelor of Arts in Science and Management from Claremont McKenna College where he was an Interdisciplinary Science Scholar. He is also currently a Kravis Fellow at the Kravis Leadership Institute.